title: Treatment of neural anosmia by topical application of basic fibroblast growth factor-gelatin hydrogel in the nasal cavity: an experimental study in mice.
abstract: OBJECTIVE
  A new treatment of neural anosmia.
  
  
  OBJECTIVE
  To investigate the effects of basic fibroblast growth factor (bFGF)-gelatin hydrogel on recovery of neural anosmia in mice.
  
  
  METHODS
  Anosmia was induced by intraperitoneal injection of 3-methylindole, 200 mg/kg. One week later, the animals underwent 1 of the following 3 procedures bilaterally: (1) group A: single-shot intranasal drip infusion of phosphate-buffered saline, (2) group B: single-shot intranasal drip infusion of bFGF, and (3) group C: placement of bFGF-gelatin hydrogel in the nasal cavity. The olfactory function of the animal was evaluated by the odor-detection test (ODT) 2 and 4 weeks later. Following the testing, the animal was killed, the thickness of the olfactory epithelium was measured, and the number of olfactory marker protein (OMP)-positive cells was counted.
  
  
  METHODS
  Research installation.
  
  
  METHODS
  Mice.
  
  
  METHODS
  The placement of bFGF-gelatin hydrogel in the nasal cavity.
  
  
  METHODS
  An ODT, thickness of olfactory epithelium, the number of OMP-positive cells
  
  
  RESULTS
  The ODT proved that neural anosmia recovered in group C but not in groups A and B. Histologically, olfactory epithelium became thicker and the number of OMP-positive cells increased in group C, while such functional and histologic recovery was poor in groups A and B. These findings suggested that placement of bFGF-gelatin hydrogel in the nasal cavity was an efficient way to facilitate recovery of neural anosmia.
  
  
  CONCLUSIONS
  As a gelatin hydrogel degrades slowly in the body, bFGF is gradually released around the site of the lesion; thus, it constantly exerts its effects on neural regeneration.
authors.affiliation: Department of Otolaryngology–Head and Neck Surgery, Ehime University, School of Medicine, Ehime, Japan. nouta313@m.ehime-u.ac.jp
authors.forename: Jumpei
authors.initials: J
authors.lastname: Nota
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Takahashi
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Hakuba
authors.forename: Naohito
authors.initials: N
authors.lastname: Hato
authors.forename: Kiyofumi
authors.initials: K
authors.lastname: Gyo
mesh_terms: D000287:Administration, Topical; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000627:therapeutic use; D005780:Gelatin / Q000008:administration & dosage; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D009296:Nasal Cavity; D000857:Olfaction Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009831:Olfactory Mucosa / Q000187:drug effects; D009832:Olfactory Nerve / Q000187:drug effects / Q000503:physiopathology; D012903:Smell / Q000502:physiology*; D016896:Treatment Outcome
chemical_list: D016222:Fibroblast Growth Factor 2; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D005780:Gelatin